Reporting the counterparty's growth as its own: management explains the company's coming year by narrating what its cust
The model's full reasoning — Q3 2023 call → NOWe need to determine if management explains the company's business direction by narrating what its counterparties are doing and scaling. The question asks: does a substantial part of management's forward account consist of reporting on the growth, expansion, ramp, adoption, or program build-out of specific customers, partners, licensees, distributors, payers, operators, or programs the company ALREADY SUPPLIES OR SERVES, such that the company's own coming volume is presented as a consequence of those parties' own trajectories rather than of the company's selling effort? We need to check the transcript. Management discusses their own sales force expansion, marketing, payer discussions, and lifecycle initiatives. They mention IDN agreements, payer formularies, and Medicaid coverage. But do they narrate the counterparties' own trajectories? For example, they mention an IDN agreement providing access to over 8 million lives, and a government retiree payer formulary adding 1.1 million lives. They say these expand the population of heart failure patients with access. They also mention that they anticipate positive impact on co-pays. But is that describing the counterparties' own scaling? The IDN is a customer, but management is not describing the IDN's own ramp or expansion; they are describing the agreement's effect on access. They also mention that they added territories and expect impact. They talk about payer discussions and anticipate more announcements. But the core of the forward account seems to be their own sales force, marketing, and product development. They do mention that they are adding territories and that new reps are trained. They also mention that they are progressing with many health plans. However, the question specifically asks if management narrates what counterparties are themselves doing and scaling. For example, are they describing the IDN's own expansion plans? No, they are describing the agreement's terms. They are not saying "our IDN partner is rolling out to more sites" or "our payer is expanding its program." They are just noting the access gained. Also, they mention that they have added a specialty pharmacy to their network to maximize access for Medicaid. That is their own action.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| EMKR | EMCORE Corporation | Q4 2023 | 2023-12-12 | C+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| PI | Impinj, Inc. | Q4 2022 | 2023-02-08 | B+ |
| FAT | FAT Brands Inc. | Q4 2021 | 2022-03-21 | F |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| PLAB | Photronics, Inc. | Q2 2017 | 2017-05-17 | C+ |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| FNV | Franco-Nevada Corporation | Q3 2016 | 2016-11-08 | B+ |
| HXL | Hexcel Corporation | Q4 2015 | 2016-01-22 | B+ |
OOMA · Q3 2022 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future volume as a consequence of those parties' trajectories.
MBLY · Q2 2023 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's volume as a consequence of those parties' trajectories.
ILMN · Q1 2018 → YESThe question is about whether management narrates what its counterparties are doing and scaling, presenting the company's future as a consequence of those parties' trajectories.